Skip to the page

Data / Drug companies / Jubilant Cadista Pharmaceuticals Inc.

Jubilant Cadista Pharmaceuticals Inc.: 82 products in the FDA NDC directory, labeler code 59746

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Jubilant Cadista Pharmaceuticals Inc. (labeler code 59746) lists 82 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 81 prescription drugs, 1 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.

The request: Watch Jubilant Cadista Pharmaceuticals Inc. (FDA labeler code 59746): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
59746
Products in commercial distribution
82
Packages
223
Finished drugs by generic name
24
Prescription products
81
Over the counter products
0
Flagged as original packager
73 of 73 products that carry the flag
Started marketing in the last 12 months
10
Earliest marketing start
March 1, 1998
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)8198.8%
Drugs for further processing11.2%

Products by type

TypeProductsShare
Prescription drugs8198.8%
Drugs for further processing11.2%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet3441.5%
Tablet, film coated2429.3%
Tablet, orally disintegrating1113.4%
Capsule67.3%
Capsule, gelatin coated33.7%
Tablet, extended release33.7%
Tablet, delayed release11.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Sildenafil59746-436Tablet, film coatedGeneric drugs (ANDA)September 1, 2026
Sildenafil59746-435Tablet, film coatedGeneric drugs (ANDA)September 1, 2026
Sildenafil59746-434Tablet, film coatedGeneric drugs (ANDA)September 1, 2026
Valsartan59746-393TabletGeneric drugs (ANDA)August 24, 2026
Eslicarbazepine Acetate59746-720TabletGeneric drugs (ANDA)May 1, 2026
Eslicarbazepine Acetate59746-719TabletGeneric drugs (ANDA)May 1, 2026
Eslicarbazepine Acetate59746-718TabletGeneric drugs (ANDA)May 1, 2026
Eslicarbazepine Acetate59746-717TabletGeneric drugs (ANDA)May 1, 2026
Roflumilast59746-802TabletGeneric drugs (ANDA)February 2, 2026
Roflumilast59746-801TabletGeneric drugs (ANDA)February 2, 2026
Risperidone59746-226TabletGeneric drugs (ANDA)October 15, 2025
Risperidone59746-225TabletGeneric drugs (ANDA)October 15, 2025
Risperidone59746-224TabletGeneric drugs (ANDA)October 15, 2025
Risperidone59746-223TabletGeneric drugs (ANDA)October 15, 2025
Risperidone59746-222TabletGeneric drugs (ANDA)October 15, 2025
Risperidone59746-221TabletGeneric drugs (ANDA)October 15, 2025
Tacrolimus59746-800Capsule, gelatin coatedGeneric drugs (ANDA)November 30, 2024
Tacrolimus59746-799Capsule, gelatin coatedGeneric drugs (ANDA)November 30, 2024
Tacrolimus59746-798Capsule, gelatin coatedGeneric drugs (ANDA)November 30, 2024
Sildenafil59746-471Tablet, film coatedGeneric drugs (ANDA)August 26, 2024
Escitalopram59746-281Tablet, film coatedGeneric drugs (ANDA)January 1, 2024
Escitalopram59746-279Tablet, film coatedGeneric drugs (ANDA)January 1, 2024
Escitalopram59746-280Tablet, film coatedGeneric drugs (ANDA)December 1, 2023
Methenamine Hippurate59746-797TabletGeneric drugs (ANDA)January 24, 2023
Carbamazepine59746-791Tablet, extended releaseGeneric drugs (ANDA)August 20, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.